Literature DB >> 28254372

Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency.

Charlene M Dawidczyk1, Luisa M Russell1, Margot Hultz1, Peter C Searson2.   

Abstract

Systemic drug delivery to a solid tumor involves a sequence of steps that determine efficacy and survival. Extravasation from circulation at the tumor site is a critical step in this sequence since it regulates how much of the drug accumulates in the tumor. Despite its importance in determining outcomes, extravasation from circulation remains a "black box." The objective of this study is to develop predictive tools for optimization of drug delivery systems. By comparing pharmacokinetics of liposomal doxorubicin in tumor-free and tumor bearing mice we quantitatively assess the rate constants for distribution, elimination, and tumor accumulation. We then relate these rate constants to the tumor-type and drug delivery system. We compare tumor accumulation in three tumor types and show a 10-fold difference between a colorectal adenocarcinoma and a pancreatic adenocarcinoma. Finally, we show how quantitative predictions of changes in tumor accumulation can be used to optimize drug delivery systems.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extravasation; Liposomes; Pharmacokinetics; Tumor accumulation

Mesh:

Substances:

Year:  2017        PMID: 28254372      PMCID: PMC5538251          DOI: 10.1016/j.nano.2017.02.008

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  32 in total

Review 1.  PEGylated nanomedicines: recent progress and remaining concerns.

Authors:  Driton Vllasaliu; Robyn Fowler; Snow Stolnik
Journal:  Expert Opin Drug Deliv       Date:  2013-12-03       Impact factor: 6.648

2.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform.

Authors:  Che-Ming J Hu; Li Zhang; Santosh Aryal; Connie Cheung; Ronnie H Fang; Liangfang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 3.  Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities.

Authors:  Zhiliang Cheng; Ajlan Al Zaki; James Z Hui; Vladimir R Muzykantov; Andrew Tsourkas
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

Review 4.  Timeline: Chemotherapy and the war on cancer.

Authors:  Bruce A Chabner; Thomas G Roberts
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

5.  Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.

Authors:  R L Hong; Y L Tseng
Journal:  Cancer       Date:  2001-05-01       Impact factor: 6.860

Review 6.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.

Authors:  Charlene M Dawidczyk; Chloe Kim; Jea Ho Park; Luisa M Russell; Kwan Hyi Lee; Martin G Pomper; Peter C Searson
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

7.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  Recommendations for Benchmarking Preclinical Studies of Nanomedicines.

Authors:  Charlene M Dawidczyk; Luisa M Russell; Peter C Searson
Journal:  Cancer Res       Date:  2015-08-06       Impact factor: 12.701

9.  'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach.

Authors:  Che-Ming J Hu; Ronnie H Fang; Brian T Luk; Kevin N H Chen; Cody Carpenter; Weiwei Gao; Kang Zhang; Liangfang Zhang
Journal:  Nanoscale       Date:  2013-04-07       Impact factor: 7.790

10.  Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts.

Authors:  M A Konerding; W Malkusch; B Klapthor; C van Ackern; E Fait; S A Hill; C Parkins; D J Chaplin; M Presta; J Denekamp
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  7 in total

1.  99mTc Stearyl 6-(benzylidenehydrazinyl) nicotinamide Liposomes as Tumor Permeability Evaluation Tracer.

Authors:  Mirel Cabrera; Nicole Lecot; Marcelo Fernández; J P Gambini; Williams Porcal; Pablo Cabral
Journal:  AAPS PharmSciTech       Date:  2021-03-24       Impact factor: 3.246

Review 2.  Antimicrobial Peptides and Cationic Nanoparticles: A Broad-Spectrum Weapon to Fight Multi-Drug Resistance Not Only in Bacteria.

Authors:  Giulia E Valenti; Silvana Alfei; Debora Caviglia; Cinzia Domenicotti; Barbara Marengo
Journal:  Int J Mol Sci       Date:  2022-05-29       Impact factor: 6.208

Review 3.  The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures.

Authors:  Atefeh Parchebafi; Farzaneh Tamanaee; Hassan Ehteram; Ejaz Ahmad; Hossein Nikzad; Hamed Haddad Kashani
Journal:  Microb Cell Fact       Date:  2022-06-18       Impact factor: 6.352

Review 4.  Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications.

Authors:  Berthony Deslouches; Y Peter Di
Journal:  Oncotarget       Date:  2017-07-11

5.  Role of Immunosuppressive Microenvironment in Acquiring Immunotolerance Post-Photothermal Therapy.

Authors:  Kondareddy Cherukula; Myung Suk Park; Adonijah Graham Sontyana; Ansuja Pulickal Mathew; Veena Vijayan; Woo Kyun Bae; In Kyu Park
Journal:  J Korean Med Sci       Date:  2019-11-18       Impact factor: 2.153

6.  Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.

Authors:  Paul C Lyon; Lucy F Griffiths; Jenni Lee; Daniel Chung; Robert Carlisle; Feng Wu; Mark R Middleton; Fergus V Gleeson; Constantin C Coussios
Journal:  J Ther Ultrasound       Date:  2017-11-02

7.  Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.

Authors:  Paul C Lyon; Michael D Gray; Christophoros Mannaris; Lisa K Folkes; Michael Stratford; Leticia Campo; Daniel Y F Chung; Shaun Scott; Mark Anderson; Robert Goldin; Robert Carlisle; Feng Wu; Mark R Middleton; Fergus V Gleeson; Constantin C Coussios
Journal:  Lancet Oncol       Date:  2018-07-11       Impact factor: 41.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.